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Objectives. We sought to explore the potential benefit of com-
bining intraaortic balloon counterpulsation (IABP) with throm-
bolysis for acute myocardial infarction (MI) complicated by
cardiogenic shock.
Background. In community hospitals, this condition is usually
managed with thrombolysis alone.
Methods. We reviewed the charts of 335 patients from two
community hospitals who presented with acute MI and had
cardiogenic shock between 1985 and 1995.
Results. Of 46 patients who underwent thrombolysis within 12 h
of acute infarction with confirmed cardiogenic shock, 27 under-
went IABP and 19 did not. Age, systolic blood pressure with shock,
pulmonary artery catheter use, pulmonary capillary wedge pres-
sure and the incidence of diabetes mellitus and anterior MI did
not differ between groups. Patients treated with IABP were
somewhat more likely to have prior MI and had a significantly
greater cardiac index (2.0 vs. 1.5 liters/min per m2, p 5 0.04).
Although no deaths occurred within 2 h of presentation, patients
not treated with IABP tended to die earlier (6.8 6 5 vs. 23.8 6
19 h, p 5 0.13). Patients treated with IABP had a significantly
higher rate of community hospital survival (93% vs. 37%, p 5
0.0002), and more of them were transferred for revascularization
(85% vs. 37%). Of 30 patients transferred for revascularization, 27
underwent angioplasty or bypass surgery; hospital survival was
74%. Patients treated with IABP also had a significantly higher
overall hospital and 1-year survival rate (67% vs. 32%, p 5 0.019).
Conclusions. Survival may be enhanced and transfer for revas-
cularization facilitated when community hospitals use both
thrombolysis and IABP to treat patients with acute MI compli-
cated by cardiogenic shock.
(J Am Coll Cardiol 1997;29:1454–8)
©1997 by the American College of Cardiology
The survival rate for cardiogenic shock in most hospitals has
changed little over the last few decades (1). Although throm-
bolytic therapy has revolutionized the treatment of community
hospital patients with myocardial infarction (MI) (2–5), those
whose infarction is complicated by severe left ventricular
failure and hypotension are rarely helped by this treatment
strategy alone (6,7), perhaps because of low infarct artery
patency rates (8,9). It is therefore not surprising that cardio-
genic shock is responsible for 58% of all hospital deaths from
infarction (7,10) and has a survival rate of ,20% in most
community hospitals (1).
Intraaortic balloon counterpulsation (IABP) theoretically
should benefit these patients, because it increases diastolic
blood pressure and significantly diminishes the work of the
heart by decreasing afterload. Unfortunately, prethrombolytic-
era randomized trials (11,12) failed to show that IABP reduced
mortality in cardiogenic shock. The use of IABP in the
thrombolytic era was discouraged after it was shown to be an
independent predictor of hemorrhagic complications (13).
This has led to a reduction in its use for cardiogenic shock after
thrombolysis in the United States (32% incidence) and else-
where (7% incidence) (14).
Recent observational studies suggest that IABP combined
with thrombolytic therapy can be safe (15,16) and reduce
mortality (17,18) in cardiogenic shock. IABP is also an impor-
tant method of stabilizing patients until they can be transferred
to tertiary care centers for acute revascularization. To further
evaluate the potential survival benefit of a strategy combining
IABP with thrombolysis in patients with MI and cardiogenic
shock who present to a community hospital within 12 h of
symptom onset, we performed a retrospective hospital chart
review.
Methods
We reviewed 335 hospital records that had discharge diag-
nosis codes for cardiogenic shock and MI from two community
hospitals (Botsford General Hospital, Garden City Hospital)
over the 10-year period from 1985 to 1995 (Fig. 1). Of these,
255 patients had confirmed cardiogenic shock, defined as
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systolic blood pressure ,90 mm Hg for .30 min not respon-
sive to fluid therapy alone, thought to be secondary to cardiac
dysfunction and associated with either signs of hypoperfusion
(cold, clammy skin, oliguria or altered sensorium) or a cardiac
index ,2.2 liters/min per m2 (in patients who underwent IABP,
the cardiac index was measured during IABP). The remaining
80 patients had shock due to septicemia or hypovolemia.
One-hundred ninety-one patients also had ST segment eleva-
tion ($1 mm in two consecutive leads) or left bundle branch
block, had cardiac enzyme levels consistent with acute MI and
were eligible for thrombolytic therapy. Only 65 patients (34%)
received thrombolytic therapy. Nineteen patients were ex-
cluded because thrombolytic therapy was started .12 h after
initial symptom onset. Therefore, 46 patients formed the study
group.
None of the patients had a contraindication for IABP
insertion. In all cases, the initial arterial puncture was achieved
with a modified Seldinger technique through the anterior
femoral artery wall with an open-ended arterial needle.
All therapies and clinical events were recorded from both
the community hospital and tertiary hospital (University of
Michigan Medical Center, Ann Arbor) records. Late end
points were obtained from the follow-up physician’s office
chart. Patients were followed up for a minimum of 1 year.
Statistical analysis. The primary end points were commu-
nity hospital survival and 30-day and 1-year mortality. Left
ventricular ejection fraction at $6 months was also evaluated
by multigated acquisition scan, echocardiogram or contrast left
ventriculogram.
Continuous variables were compared with a Student t test
(two-tailed). Categoric variables were compared with a chi-
square test. Continuous variables are reported as mean
value 6 SD. Categoric variables are reported as frequencies
and percentages. A p value , 0.05 was considered significant.
Results
Of the 46 study patients, 27 received both thrombolytic
therapy and IABP; 19 received thrombolytic therapy alone.
The groups did not differ significantly by age, systolic blood
pressure with shock, time to thrombolytic treatment, the
proportion of male patients or the incidence of anterior MI
(Table 1). Patients treated with IABP had a slightly greater
incidence of prior MI and presented significantly more often
with Killip class I. Balloon pumps were placed an average of
3.2 h after thrombolytic therapy (an average of 5.7 h from the
onset of chest pain).
The use of pulmonary artery catheters was similar between
groups, but more patients treated without IABP required
mechanical ventilation and vasopressor therapy (Table 2). In
the 16 patients from the community hospital who had a
pulmonary artery catheter placed, mean pulmonary capillary
wedge pressure (after balloon inflation in patients with IABP)
did not differ with the use of IABP, but the cardiac index
(during IABP use) was higher in patients treated with IABP
(mean 2.0 vs. 1.5 liters/min per m2, p 5 0.041).
Community hospital complications are shown in Table 3.
Patients not treated with IABP had somewhat more asystole
and significantly more atrioventricular block than patients so
Abbreviations and Acronyms
IABP 5 intraaortic balloon counterpulsation
MI 5 myocardial infarction
TAMI 5 Thrombolysis and Angioplasty in Myocardial Infarction
Figure 1. Flow diagram of the study pa-
tients. Survival is indicated in italics below
the subgroup description.
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treated. The complications associated with IABP use were
infrequent (15% overall).
Survival. All patients in both treatment groups survived
$2.2 h after admission to the emergency department. The
shortest time from the identification of cardiogenic shock to
death was 1.8 h, allowing enough time for insertion of a
balloon pump in both groups. The mean time from emergency
department presentation to balloon pump insertion was 4.4 h.
Among patients who died in the community hospital, the time
from chest pain to death, emergency department presentation
to death and diagnosis of cardiogenic shock to death did not
differ between treatment groups (Table 4).
Significantly more patients treated with IABP survived the
community hospital stay (93% vs. 37% treated without IABP,
p 5 0.0002) (Table 4, Fig. 1). Four patients treated with IABP
remained in the community hospital; two survived. Of the 12
patients not treated with IABP who remained in the commu-
nity hospital, none survived.
Thirty patients (65%) were transferred to a tertiary care
Table 1. Baseline Characteristics of Patients With Acute Myocardial
Infarction and Cardiogenic Shock Treated With or Without
Intraaortic Balloon Counterpulsation
IABP
(n 5 27)
No IABP
(n 5 19)
p
Value
Demographics
Male 16 (59%) 12 (63%) 0.79
Age (yr) 62 6 12 64 6 13 0.58
Risk factors
DM 7 (26%) 5 (26%) 0.98
Previous MI 6 (22%) 1 (5%) 0.25
Stroke 1 (4%) 0 (0%) 0.40
CHF 1 (4%) 2 (11%) 0.36
CABG 0 (0%) 0 (0%) —
Hypertension 10 (37%) 11 (58%) 0.16
PVD 0 (0%) 1 (5%) 0.23
Medication on admission
Aspirin 2 (7%) 0 (0%) 0.23
Warfarin 0 (0%) 0 (0%) —
Beta-blocker 3 (11%) 1 (5%) 0.49
Ca channel blocker 6 (22%) 2 (11%) 0.30
ACE inhibitor 3 (11%) 2 (11%) 0.95
Presentation characteristics
Shock on entry 9 (33%) 9 (47%) 0.34
HR (beats/min) 78 6 25 77 6 25 0.86
SBP (mm Hg) 112 6 36 113 6 35 0.95
SBP with shock (mm Hg) 73 6 14 83 6 9 0.13
Anterior MI 11 (40%) 8 (42%) 0.93
Admission Killip class
I 14 (52%) 4 (21%) 0.035
II 3 (11%) 4 (21%) 0.36
III 1 (4%) 2 (11%) 0.36
IV 9 (33%) 9 (47%) 0.34
Time from chest pain onset to
thrombolysis (h)
2.5 6 3.1 3.6 6 2.8 0.21
Time from chest pain onset to
IABP (h)
5.7 6 4.0 — —
Data presented are number (%) of patients or mean value 6 SD. ACE 5
angiotensin-converting enzyme; Ca 5 calcium; CABG 5 coronary artery bypass
graft surgery; CHF 5 congestive heart failure; DM 5 diabetes mellitus; HR 5
heart rate; IABP 5 intraaortic balloon counterpulsation; MI 5 myocardial
infarction; PVD 5 peripheral vascular disease; SBP 5 systolic blood pressure.
Table 2. In-Hospital Course of Patients With Acute Myocardial
Infarction and Cardiogenic Shock Treated With or Without
Intraaortic Balloon Counterpulsation
IABP
(n 5 27)
No IABP
(n 5 19)
p
Value
Thrombolytic agent
rt-PA 16 (59%) 13 (68%) 0.53
Streptokinase 11 (41%) 6 (32%) 0.53
Laboratory results
Hematocrit (%) 40 6 4 41 6 6 0.61
Platelet count (3 1,000/mm3) 266 6 72 289 6 76 0.31
Prothrombin time (s) 12 6 0.5 13 6 4 0.22
Medical therapy
Dobutamine 10 (37%) 10 (53%) 0.29
Dopamine 24 (89%) 18 (95%) 0.49
NE bitartrate 8 (30%) 11 (58%) 0.06
Procedure
Cardioversion 2 (7%) 4 (21%) 0.18
Ventilator 7 (26%) 12 (63%) 0.01
Pacemaker 9 (33%) 10 (53%) 0.19
PA catheter* 11 (41%) 5 (26%) 0.31
CWP (mm Hg) 22 6 10 25 6 14 0.73
CI (liters/min per m2)* 2.0 6 0.5 1.5 6 0.4 0.04
*In the community hospital, after balloon insertion among patients with
intraaortic balloon counterpulsation (IABP). Data presented are number (%) of
patients or mean value 6 SD. CI 5 cardiac index; CWP 5 capillary wedge
pressure; NE 5 norepinephrine; PA 5 pulmonary artery; rt-PA 5 recombinant
tissue-type plasminogen activator.
Table 3. Community Hospital Complications of Patients With Acute
Myocardial Infarction and Cardiogenic Shock Treated With or
Without Intraaortic Balloon Counterpulsation
IABP
(n 5 27)
No IABP
(n 5 19)
p
Value
AV block 7 (26%) 11 (58%) 0.03
Asystole 4 (15%) 7 (37%) 0.09
Sustained VT 6 (22%) 7 (37%) 0.28
VF 3 (11%) 5 (26%) 0.18
Mitral regurgitation 1 (4%) 0 (0%) 0.40
VSD 2 (7%) 0 (0%) 0.23
Recurrent ischemia 11 (41%) 5 (33%) 0.31
Recurrent infarction 6 (22%) 2 (13%) 0.15
Stroke
Hemorrhagic 0 (0%) 0 (0%) —
Nonhemorrhagic 2 (7%) 0 (0%) 0.23
Balloon pump complications
Hematoma .3 cm 1 (4%) — —
Bleeding requiring transfusion 1 (4%) — —
Bacteremia 1 (4%) — —
Pseudoaneurysm 1 (4%) — —
Total 4 (15%) — —
Data presented are number (%) of patients. For the intraaortic balloon
counterpulsation (IABP) group, complications occurring after balloon place-
ment are shown. AV 5 atrioventricular; VF 5 ventricular fibrillation; VSD 5
ventricular septal defect; VT 5 ventricular tachycardia.
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center, and 22 (73%) survived. More patients treated with
IABP were transferred for revascularization (85% vs. 37%). Of
the 23 patients treated with IABP who were transferred, 16
(70%) survived compared with 6 (86%) of 7 transferred
patients not so treated. Twenty-seven (90%) of the 30 patients
who were transferred underwent either coronary angioplasty
or bypass surgery. Eight (67%) of 12 patients who underwent
angioplasty, 10 (83%) of 12 who underwent bypass grafting and
2 (67%) of 3 who underwent both procedures survived, for an
overall survival rate with revascularization of 20 (74%) of 27.
The overall hospital and 1-year survival rate was 67% in
patients treated with IABP versus 32% in those not so treated
(p 5 0.019).
The ejection fraction beyond 6 months was evaluated in 10
patients (56%) treated with IABP and 5 (83%) treated without
IABP; the results did not differ significantly (42 6 13% vs.
45 6 21%, p 5 0.79).
Discussion
Each year, up to 70,000 patients die of MI complicated by
cardiogenic shock (19). Most of these patients are first treated
in a community hospital, where angiographic and surgical
facilities may be unavailable. Treatment options in these
centers include thrombolytic therapy or immediate transfer to
a tertiary care facility for angiography and revascularization,
but many patients will remain at the local hospital because
physicians are reluctant to transfer hemodynamically unstable
patients. This observational study suggests that when early
IABP support is used in conjunction with thrombolysis, short-
and long-term survival can be enhanced, primarily because of
the increased opportunity for transfer and revascularization.
Thrombolysis alone may not reduce mortality in these high
risk patients (6), and IABP alone has not proved to be an
effective alternative. Two small randomized trials (11,12) that
each examined ,50 patients with MI and cardiogenic shock
showed no survival benefit with IABP, but both trials were
performed before thrombolytic therapy became the standard
treatment for MI. More recent observational data suggest that
IABP can be used safely (15,16) and may reduce mortality in
patients with MI complicated by cardiogenic shock (17,18).
These findings may be a result of enhanced thrombolysis,
improved infarct artery patency, decreased reocclusion, or
supported ventricular function (while ischemically stunned
myocardium recovers). Our data support this concept: Patients
who received both IABP and thrombolytic therapy rather than
thrombolysis alone had better community-hospital, 30-day and
1-year survival rates.
Nonrandomized data (18,20) also suggest that revascular-
ization, when available, is associated with a survival advantage.
Two multicenter international trials, SHOCK (SHould we
emergently revascularize Occluded Coronaries for cardiogenic
shocK) and SMASH (Swiss Multicenter study of Angioplasty
for SHock following myocardial infarction), are currently
addressing this issue. Meanwhile, the decision to use throm-
bolytic therapy, IABP, or both, or to transfer critically ill
patients to tertiary care centers for revascularization remains
in dispute among community hospital physicians. It may be
that the best use of IABP is as a bridge until transfer and
revascularization can be performed. Of the 30 patients in our
study who survived to be transferred, 23 (77%) had been
treated with IABP. Of the 191 patients with shock and MI in
our study, 126 (66%) did not receive thrombolytic agents. Of
such patients who remained in the community hospital, only 6
(5%) survived to be discharged home. Prompt stabilization and
transfer may be even more important for these patients, for
whom IABP was rarely used as an initial treatment.
Preclinical studies. Through enhanced diastolic augmen-
tation, IABP may improve thrombolysis (21) and promote
coronary blood flow (22), which resulted in improved survival
and myocardial salvage in one study of a hypotensive canine
model of MI (23). In a normotensive model (24), IABP
reduced the reperfusion time after recombinant tissue-type
plasminogen activator (rt-PA) administration from 39 to
13 min. Coronary blood flow velocity was not affected, indicat-
ing that the IABP-augmented diastolic pressure caused the
improvement in rate of thrombolysis.
Previous community hospital studies. In a previous obser-
vational study at our institution (17), 13 patients with MI and
cardiogenic shock received thrombolytic therapy, 29 received
IABP alone and 22 received both interventions. The survival
rate was 68% with the combined treatments compared with
23% for thrombolytic therapy alone and 28% for IABP alone
(p 5 0.005). Similar to the current study, these initial obser-
vations suggest a survival advantage when IABP is combined
with thrombolytic therapy. However, in contrast to the current
study, cardiogenic shock developed in many of these patients
.12 h after hospital admission, and 29 patients received IABP
support without thrombolysis.
Complications. The complication rate of balloon pump
insertion after thrombolysis was low in our two previous
studies (15,17). In contrast, the TAMI (Thrombolysis and
Angioplasty in Myocardial Infarction) study (13) showed that
balloon pump insertion resulted in almost a 5-fold higher risk
Table 4. Survival of Patients With Acute Myocardial Infarction and
Cardiogenic Shock Treated With and Without Intraaortic
Balloon Counterpulsation
IABP
(n 5 27)
No IABP
(n 5 19)
p
Value
Time from
Chest pain onset to death (h) 25.6 6 19 8.2 6 5 0.13
Emergency dept arrival
to death (h)
23.8 6 19 6.8 6 5 0.13
Cardiogenic shock diagnosis
to death (h)
22.5 6 19 6.3 6 5 0.14
Survived
Community hospital 25 (93%) 7 (37%) 0.0002
30 days 18 (67%) 6 (32%) 0.019
1 yr 18 (67%) 6 (32%) 0.019
Data presented are number (%) of patients or mean value 6 SD. dept 5
department; IABP 5 intraaortic balloon counterpulsation.
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of severe hemorrhagic or vascular complications. The disparity
between the complication rate in the TAMI study and ours
may be explained by our insertion technique (see Methods).
Limitations of the study. Our retrospective study was
specifically designed to analyze the survival benefits of intra-
venous thrombolysis in conjunction with IABP within 12 h of
symptom onset in patients with MI complicated by cardiogenic
shock. We were limited by the small number of patients who
manifested cardiogenic shock and received thrombolytic ther-
apy within 12 h of symptom onset. We chose the 12-h cutoff
point because of the limited benefit of thrombolysis after this
time (25,26). Given the nonrandomized and retrospective
nature of our observations, with the inherent danger of selec-
tion bias, these data should be interpreted with some caution,
although the groups were matched for variables known to
predict adverse outcome in patients with cardiogenic shock.
Further, both groups were attended by invasive cardiologists
with expertise in cardiac catheterization and balloon pump
insertion, and their treatment strategies were similar (i.e., early
stabilization and transfer to a tertiary care center for interven-
tion whenever possible). Nonetheless, large prospective ran-
domized studies will be required to define the best treatment
strategy for patients in community hospitals who have MI
complicated by cardiogenic shock.
Conclusions. This study suggests that survival is enhanced
and transfer for revascularization facilitated when patients
with MI complicated by cardiogenic shock who present to a
community hospital undergo thrombolysis and IABP rather
than thrombolysis alone. This strategy is undergoing pro-
spective, randomized evaluation in the Thrombolysis And
Counterpulsation To Improve Cardiogenic Shock survival
(TACTICS) trial.
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